LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 9 von insgesamt 9

Suchoptionen

  1. Artikel ; Online: Effect of CytoSorb on Interleukin-6.

    Waalders, Nicole J B / Jansen, Aron / Pickkers, Peter

    Critical care medicine

    2024  Band 52, Heft 3, Seite(n) e152–e153

    Mesh-Begriff(e) Interleukin-6
    Chemische Substanzen Interleukin-6
    Sprache Englisch
    Erscheinungsdatum 2024-02-21
    Erscheinungsland United States
    Dokumenttyp Letter ; Comment
    ZDB-ID 197890-1
    ISSN 1530-0293 ; 0090-3493
    ISSN (online) 1530-0293
    ISSN 0090-3493
    DOI 10.1097/CCM.0000000000006120
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo.

    Jansen, Aron / Waalders, Nicole J B / van Lier, Dirk P T / Kox, Matthijs / Pickkers, Peter

    Critical care (London, England)

    2023  Band 27, Heft 1, Seite(n) 117

    Abstract: Background: The CytoSorb hemoadsorption device has been demonstrated to be capable of clearing inflammatory cytokines, but has not yet been shown to attenuate plasma cytokine concentrations. We investigated the effects of CytoSorb hemoperfusion on ... ...

    Abstract Background: The CytoSorb hemoadsorption device has been demonstrated to be capable of clearing inflammatory cytokines, but has not yet been shown to attenuate plasma cytokine concentrations. We investigated the effects of CytoSorb hemoperfusion on plasma levels of various cytokines using the repeated human experimental endotoxemia model, a highly standardized and reproducible human in vivo model of systemic inflammation and immunological tolerance induced by administration of bacterial lipopolysaccharide (LPS).
    Methods: Twenty-four healthy male volunteers (age 18-35) were intravenously challenged with LPS (a bolus of 1 ng/kg followed by continuous infusion of 0.5 ng/kg/hr for three hours) twice: on day 0 to quantify the initial cytokine response and on day 7 to quantify the degree of endotoxin tolerance. Subjects either received CytoSorb hemoperfusion during the first LPS challenge (CytoSorb group), or no intervention (control group). Plasma cytokine concentrations and clearance rates were determined serially. This study was registered at ClinicalTrials.gov (NCT04643639, date of registration November 24th 2020).
    Results: LPS administration led to a profound increase in plasma cytokine concentrations during both LPS challenge days. Compared to the control group, significantly lower plasma levels of tumor necrosis factor (TNF, - 58%, p < 0.0001), interleukin (IL)-6 ( - 71%, p = 0.003), IL-8 ( - 48%, p = 0.02) and IL-10 ( - 26%, p = 0.03) were observed in the CytoSorb group during the first LPS challenge. No differences in cytokine responses were observed during the second LPS challenge.
    Conclusions: CytoSorb hemoperfusion effectively attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo, whereas it does not affect long-term immune function. Therefore, CytoSorb therapy may be of benefit in conditions characterized by excessive cytokine release.
    Mesh-Begriff(e) Humans ; Male ; Adolescent ; Young Adult ; Adult ; Cytokines ; Hemoperfusion ; Lipopolysaccharides ; Interleukin-6 ; Inflammation
    Chemische Substanzen Cytokines ; Lipopolysaccharides ; Interleukin-6
    Sprache Englisch
    Erscheinungsdatum 2023-03-21
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 2041406-7
    ISSN 1466-609X ; 1364-8535
    ISSN (online) 1466-609X
    ISSN 1364-8535
    DOI 10.1186/s13054-023-04391-z
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: Effect of anakinra in COVID-19.

    Kooistra, Emma J / Waalders, Nicole J B / Kox, Matthijs / Pickkers, Peter

    The Lancet Rheumatology

    2020  Band 2, Heft 9, Seite(n) e523–e524

    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-07-24
    Erscheinungsland England
    Dokumenttyp Journal Article
    ISSN 2665-9913
    ISSN (online) 2665-9913
    DOI 10.1016/S2665-9913(20)30235-6
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions.

    Kox, Matthijs / Waalders, Nicole J B / Kooistra, Emma J / Gerretsen, Jelle / Pickkers, Peter

    JAMA

    2020  

    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-09-03
    Erscheinungsland United States
    Dokumenttyp Journal Article
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2020.17052
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Effect of anakinra in COVID-19

    Kooistra, Emma J / Waalders, Nicole J B / Kox, Matthijs / Pickkers, Peter

    The Lancet Rheumatology

    2020  Band 2, Heft 9, Seite(n) e523–e524

    Schlagwörter covid19
    Sprache Englisch
    Verlag Elsevier BV
    Erscheinungsland us
    Dokumenttyp Artikel ; Online
    ISSN 2665-9913
    DOI 10.1016/s2665-9913(20)30235-6
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  6. Artikel: Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions

    Kox, Matthijs / Waalders, Nicole J B / Kooistra, Emma J / Gerretsen, Jelle / Pickkers, Peter

    JAMA

    Schlagwörter covid19
    Verlag WHO
    Dokumenttyp Artikel
    Anmerkung WHO #Covidence: #915080
    Datenquelle COVID19

    Kategorien

  7. Artikel ; Online: Cytokine Levels in Critically Ill Patients With COVID-19 and Other Conditions

    Kox, Matthijs / Waalders, Nicole J. B. / Kooistra, Emma J. / Gerretsen, Jelle / Pickkers, Peter

    JAMA

    2020  Band 324, Heft 15, Seite(n) 1565

    Schlagwörter General Medicine ; covid19
    Sprache Englisch
    Verlag American Medical Association (AMA)
    Erscheinungsland us
    Dokumenttyp Artikel ; Online
    ZDB-ID 2958-0
    ISSN 1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
    ISSN (online) 1538-3598
    ISSN 0254-9077 ; 0002-9955 ; 0098-7484
    DOI 10.1001/jama.2020.17052
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  8. Artikel ; Online: Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study.

    Kooistra, Emma J / Waalders, Nicole J B / Grondman, Inge / Janssen, Nico A F / de Nooijer, Aline H / Netea, Mihai G / van de Veerdonk, Frank L / Ewalds, Esther / van der Hoeven, Johannes G / Kox, Matthijs / Pickkers, Peter

    Critical care (London, England)

    2020  Band 24, Heft 1, Seite(n) 688

    Abstract: Background: A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of ... ...

    Abstract Background: A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases. We investigated the effects of anakinra on inflammatory parameters and clinical outcomes in critically ill, mechanically ventilated COVID-19 patients with clinical features of hyperinflammation.
    Methods: In this prospective cohort study, 21 critically ill COVID-19 patients treated with anakinra were compared to a group of standard care. Serial data of clinical inflammatory parameters and concentrations of multiple circulating cytokines were determined and aligned on start day of anakinra in the treatment group, and median start day of anakinra in the control group. Analysis was performed for day - 10 to + 10 relative to alignment day. Clinical outcomes were analyzed during 28 days. Additionally, three sensitivity analyses were performed: (1) using propensity score-matched groups, (2) selecting patients who did not receive corticosteroids, and (3) using a subset of the control group aimed to match the criteria (fever, elevated ferritin) for starting anakinra treatment.
    Results: Baseline patient characteristics and clinical parameters on ICU admission were similar between groups. As a consequence of bias by indication, plasma levels of aspartate aminotransferase (ASAT) (p = 0.0002), ferritin (p = 0.009), and temperature (p = 0.001) were significantly higher in the anakinra group on alignment day. Following treatment, no relevant differences in kinetics of circulating cytokines were observed between both groups. Decreases of clinical parameters, including temperature (p = 0.03), white blood cell counts (p = 0.02), and plasma levels of ferritin (p = 0.003), procalcitonin (p = 0.001), creatinine (p = 0.01), and bilirubin (p = 0.007), were more pronounced in the anakinra group. No differences in duration of mechanical ventilation or ICU length of stay were observed between groups. Sensitivity analyses confirmed these results.
    Conclusions: Anakinra is effective in reducing clinical signs of hyperinflammation in critically ill COVID-19 patients. A randomized controlled trial is warranted to draw conclusion about the effects of anakinra on clinical outcomes.
    Mesh-Begriff(e) Aged ; COVID-19/drug therapy ; COVID-19/physiopathology ; Cohort Studies ; Critical Illness/therapy ; Female ; Humans ; Interleukin 1 Receptor Antagonist Protein/adverse effects ; Interleukin 1 Receptor Antagonist Protein/pharmacology ; Interleukin 1 Receptor Antagonist Protein/therapeutic use ; Male ; Middle Aged ; Pandemics/prevention & control ; Pandemics/statistics & numerical data ; Prospective Studies ; Receptors, Interleukin-1/antagonists & inhibitors ; Receptors, Interleukin-1/therapeutic use ; Statistics, Nonparametric
    Chemische Substanzen Interleukin 1 Receptor Antagonist Protein ; Receptors, Interleukin-1
    Sprache Englisch
    Erscheinungsdatum 2020-12-10
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2041406-7
    ISSN 1466-609X ; 1364-8535
    ISSN (online) 1466-609X
    ISSN 1364-8535
    DOI 10.1186/s13054-020-03364-w
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang